Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study.

CONCLUSIONS: Patients with daily frequency and MO show a clinical improvement in short-term. Patients with comorbidities who start treatment earlier in the course of the disease need a longer duration of treatment. The profile of response to treatment with OnabotulinumtoxinA determines its minimum treatment duration and the timepoint of a meaningful response. PMID: 32086801 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32086801?dopt=Abstract

Source: Headache - February 21, 2020 Category: Neurology Authors: Alpuente A, Gallardo VJ, Torres-Ferrús M, Álvarez-Sabin J, Pozo-Rosich P Tags: Headache Source Type: research